Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, University of Bonn, 53127, Bonn, Germany.
Department of Dermatology, Venereology and Allergology, University Hospital Essen, University of Duisburg-Essen, 45112, Essen, Germany.
Int J Cancer. 2019 Apr 1;144(7):1645-1656. doi: 10.1002/ijc.31874. Epub 2019 Jan 9.
Activation of the innate immune receptor retinoic acid-inducible gene I (RIG-I) by its specific ligand 5'-triphosphate RNA (3pRNA) triggers anti-tumor immunity, which is dependent on natural killer (NK) cell activation and cytokine induction. However, to date, RIG-I expression and the functional consequences of RIG-I activation in NK cells have not been examined. Here, we show for the first time the expression of RIG-I in human NK cells and their activation upon RIG-I ligand (3pRNA) transfection. 3pRNA-activated NK cells killed melanoma cells more efficiently than NK cells activated by type I interferon. Stimulation of RIG-I in NK cells specifically increased the surface expression of membrane-bound TNF-related apoptosis-inducing ligand (TRAIL) on NK cells, while activated NK cell receptors were not affected. RIG-I-induced membrane-bound TRAIL initiated death-receptor-pathway-mediated apoptosis not only in allogeneic but also in autologous human leukocyte antigen (HLA) class I-positive and HLA class I-negative melanoma cells. These results identify the direct activation of RIG-I in NK cells as a novel mechanism for how RIG-I can trigger enhanced NK cell killing of tumor cells, underscoring the potential of RIG-I activation for tumor immunotherapy.
天然免疫受体视黄酸诱导基因 I(RIG-I)被其特定配体 5'-三磷酸 RNA(3pRNA)激活可引发抗肿瘤免疫,该过程依赖于自然杀伤(NK)细胞的激活和细胞因子的诱导。然而,迄今为止,RIG-I 在 NK 细胞中的表达及其激活的功能后果尚未被研究。在此,我们首次证明了 RIG-I 在人 NK 细胞中的表达及其在 RIG-I 配体(3pRNA)转染后的激活。3pRNA 激活的 NK 细胞比 I 型干扰素激活的 NK 细胞更有效地杀伤黑色素瘤细胞。RIG-I 在 NK 细胞中的刺激特异性地增加了 NK 细胞表面结合的 TNF 相关凋亡诱导配体(TRAIL)的表达,而激活的 NK 细胞受体不受影响。RIG-I 诱导的膜结合 TRAIL 不仅可诱导同种异体 HLA Ⅰ类阳性和 HLA Ⅰ类阴性黑色素瘤细胞,还可诱导受体死亡通路介导的凋亡。这些结果确定了 RIG-I 在 NK 细胞中的直接激活是 RIG-I 如何增强 NK 细胞杀伤肿瘤细胞的新机制,突出了 RIG-I 激活用于肿瘤免疫治疗的潜力。